CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024 15:55 ET
|
Science 37, Inc.
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
Verana Health Committed to Revolutionizing Clinical Trials with Enhancements to SaaS Applications
June 12, 2024 09:00 ET
|
Verana Health, Inc.
SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), announces new...
Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024 08:00 ET
|
Science 37, Inc.
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
June 12, 2024 08:00 ET
|
Quoin Pharmaceuticals, Inc.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...
Global mRNA Cancer Vaccines Clinical Trials Market Report 2024: First Commercial mRNA Vaccine Approval Expected by 2029
June 12, 2024 07:32 ET
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024" drug pipelines has been added to ResearchAndMarkets.com's...
CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials
June 11, 2024 09:00 ET
|
CanaQuest Medical Corp.
Appointee, formerly with GW Pharma (subsidiary), brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex®) TORONTO, ON, June 11, 2024 ...
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
June 11, 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
Decentralised Clinical Trials Market Report 2024-2034
June 11, 2024 06:57 ET
|
Research and Markets
Dublin, June 11, 2024 (GLOBE NEWSWIRE) -- The "Decentralised Clinical Trials Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Decentralised...
Clinical Trial Supply and Logistics Market for Pharma 2024-2034: Virtual Trials and Technology Are Gaining Acceptance among Patients and Sites
June 10, 2024 08:54 ET
|
Research and Markets
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Supply and Logistics Market for Pharma 2024-2034" report has been added to ResearchAndMarkets.com's offering.World revenue for the...
Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035
June 10, 2024 08:12 ET
|
Research and Markets
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035" report has been added to ...